Whooping Cough Or Pertussis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Whooping Cough Or Pertussis Market Outlook

Thelansis’s “Whooping Cough Or Pertussis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Whooping Cough Or Pertussis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Whooping Cough Or Pertussis Overview

Pertussis (commonly known as whooping cough), a respiratory infection, is caused by the gram-negative coccobacillus Bordetella pertussis and Bordetella parapertussis. The infection is spread through airborne droplets and is highly contagious, with a tendency to affect 100% of non-immune household contacts. Protection from vaccination may wane to 50% within 12 years of completion, and immunocompromised individuals may also contract Bordetella bronchiseptica, commonly known as “kennel cough.” Risk factors for acquiring pertussis include pregnancy, epidemic exposure, lack of immunization, and close contact with an infected individual. The organism adheres to ciliated respiratory epithelial cells, causing local inflammatory changes in the mucosal lining and releasing toxins that act locally and systemically. Pertussis presents similarly to other respiratory infections but has a distinct progression through three phases and a persistent cough without fever. Infants and older adults have higher mortality and morbidity, respectively, with a 2% death rate in infants accounting for 96% of pertussis-related deaths. Most individuals with pertussis will recover, although the illness may last several months. Secondary complications such as pneumonia, seizures, and encephalopathy may occur. Secondary bacterial pneumonia is commonly caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Staphylococcus aureus, while viral infections include a respiratory syncytial virus, cytomegalovirus, and adenovirus may also occur.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Whooping Cough Or Pertussis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034